Ke. Dusenbery et al., AUTOLOGOUS BONE-MARROW TRANSPLANTATION EV ACUTE MYELOID-LEUKEMIA - THE UNIVERSITY-OF-MINNESOTA EXPERIENCE, International journal of radiation oncology, biology, physics, 36(2), 1996, pp. 335-343
Citations number
25
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: To report the outcome of autologous bone marrow transplantati
on for patients with acute myeloid leukemia (AML) in first or greater
complete remission (CR) treated by autologous bone marrow transplantat
ion using two different preparatory regimens. Methods and Materials: B
etween September 1986 and August 1993, 75 patients with AML ranging in
age from 6 months to 58 years underwent autologous bone marrow transp
lantation using previously harvested and frozen unpurged (n = 6) or 4-
hydroperoxycyclophosphamide purged marrows (n = 69). Patients were in
first CR (n = 44) or beyond first CR (n = 31). The preparative regimen
consisted of 120 mg/kg of cyclophosphamide (CY) and 1320 cGy total bo
dy irradiation (TBI) in eight fractions over 4 days (CY/TBI) in 29 pat
ients; and 16 mg/kg of Busulfan (BU) and 200 mg/kg of CY (BU/CY) in 46
patients. Thirty-five of these 75 patients (18 CY/TBI and 17 BU/CY) m
ere part of a randomized trial comparing the two preparative regimens.
Results: At 2 years, overall survival and disease-free survival (DFS)
were 49% [95% confidence interval (C.I.) 37-61%] and 33% (95% C.I. 32
-55%), respectively. Patients in first CR had a significantly better o
utcome than patients beyond first CR with an estimated 2-year DFS of 5
9% (95% C.I. 44-74%) vs. 21% (95% C.I. 5-36%, log-rank p = 0.0001), re
spectively. For patients conditioned with CY/TBI, the estimated 2-year
DFS was 52% compared to 39% for BU/CY (log-rank p = 0.35). Estimated
2-year relapse rates were 44% vs. 56% (log-rank p = 0.40), respectivel
y. For patients in first CR, no differences in DFS were observed betwe
en the two regimens (2-year estimates 69% vs. 55% log-rank p = 0.52).
Patients beyond first CR had a significantly improved DFS with the CY/
TBI regimen (2-year estimates of 38% vs. 7%, log-rank p = 0.04). No di
fferences were found between the two regimens in terms of time to WBC
engraftment, absolute neutrophil count of > 500, incidence of bacterem
ias, or median time to hospital discharge. Interstitial pneumonitis de
veloped in two patients (one BU/CY, one CY/TBI) and venoocclusive dise
ase developed in seven BU/CY patients (Fishers exact test p = 0.04). C
onclusions: For patients beyond first CR, the CY/TBI regimen provided
a better outcome, with a significantly better disease-free survival an
d less venoocclusive disease. For patients in first CR, no significant
difference between the two regimens was found. The high relapse rate,
especially for patients with advanced disease, emphasizes the need fo
r early transplantation and for new strategies to improve outcome. Cop
yright (C) 1996 Elsevier Science Inc.